Introduction
============

Transient low-level HIV type-1 (HIV) plasma viremias (LLV; 30--1000 RNA copies/ml) can be detected in a subset of participants during antiretroviral therapy (ART) that otherwise suppresses HIV replication to below the limits of detection by commercial assays \[[@R1]--[@R4]\]. LLV have been associated with low pretreatment CD4^+^ T-cell nadirs \[[@R5],[@R6]\] and higher pretreatment plasma HIV RNA loads \[[@R1],[@R7],[@R8]\]. During ART, LLV have been linked to microbial translocation and inflammation \[[@R4],[@R9]\], and in some cases to poor adherence to ART \[[@R7],[@R10],[@R11]\]. The causes and clinical significance of LLV remain controversial because at least two processes appear to contribute to this phenomenon \[[@R10],[@R12]\]. First, the detection of multiple identical HIV sequences in a LLV plasma from an individual who initiates ART after viral diversification suggests synchronous production of virions from a clone of infected cells \[[@R13],[@R14]\]. Second, the detection of multiple LLV HIV sequences that show time-ordered evolution in phylogenetic analyses and/or selection of novel resistance mutations suggests full cycles of HIV replication \[[@R10],[@R15]\].

The current study was undertaken to further explore potential mechanisms causing LLV, as these appear to constitute a viral reservoir that persists during effective ART. We hypothesized a linkage between systemic inflammation and production of virions from clones of HIV-infected cells detected as identical LLV sequences in plasma.

Methods
=======

Study design
------------

HIV-infected ART-naive men and women initiating a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART regimen at Hospital Nacional Dos de Mayo in Lima, Peru enrolled in a 24-month observational study after written informed consent, as approved by Institutional Review Boards \[[@R16]\]. Plasma HIV RNA was quantified prior to treatment initiation, and thereafter quarterly. LLV were defined as plasma HIV RNA 30--1000  copies/ml after at least one specimen following ART initiation tested less than 30 copies/ml. Virologic failure was defined as viremia greater than 1000 copies/ml at two consecutive time-points.

Among participants with ART suppression (median plasma HIV RNA \<30 copies/ml) during the study, the pre-ART plasma HIV RNA, peripheral blood mononuclear cell (PBMC) HIV DNA, and biomarkers of inflammation were compared between those with and without LLV, and within participants at time-points with and without LLV. HIV *env* and *pol* sequences derived from LLV were assessed in phylogenetic analyses for diversity and divergence compared with pre-ART plasma and PBMC sequences, and for drug-resistance mutations. Adherence to ART was assessed by participants' recall using questionnaires and by measuring nevirapine (NVP) concentrations, as most participants' therapy included this antiretroviral, which has a relatively long half-life. Potential drug--drug interactions between NVP and rifampin, the latter given to treat suspected or proven disease because of *Mycobacterium tuberculosis* (MTB), were assessed by review of the medication logs recorded at each study visit.

HIV RNA and DNA quantification in plasma and single genome amplification of HIV *env* and *pol*
-----------------------------------------------------------------------------------------------

Plasma HIV RNA was quantified in duplicate from each specimen using a CLIA-compliant in-house real-time *gag* reverse transcription-PCR with a lower limit of quantification (LLQ) of 30 copies/ml \[[@R17],[@R18]\]. Detection of RNA between 1 and 29 copies/ml was designated as below LLQ (BLLQ), and if no RNA was detected as 'target not detected' (TND). HIV RNA quantification was performed in the UW Retrovirology Laboratory certified by the College of American Pathologists and the US National Institutes of Health\'s Virology Quality Assurance (VQA) Program. Participants with ART suppression were categorized as (+) or (−) for detection of LLV, as defined above. HIV RNA and cell-free HIV DNA in plasma or serum (167 μl) were quantified by RT-PCR; HIV DNA was measured in LLV to determine whether it contributed to detection of HIV RNA. HIV DNA was quantified in PBMC before and during ART by a real-time PCR that amplifies a region of the LTR-*gag* with reproducible detection of 10 c per PCR \[[@R19]\].

To evaluate the genotypes of HIV *env* C2-V5 and a region of *pol* encoding protease and reverse transcriptase, cDNA from LLV and pre-ART plasma and PBMC DNA were diluted to single copy \[[@R20]\], followed by SGA and direct sequencing \[[@R10]\]. SGA sequences were aligned using the MUSCLE algorithm in Geneious (BioMatters, Newark, New Jersey, USA), with maximum likelihood trees generated using PhyML in DIVEIN \[[@R18]\]. Phylogenetic patterns of HIV *env* and *pol* sequences were defined for analysis as: monotypic, if 50--100% of their LLV sequences derived by SGA were identical to other sequences from the specimen; or diverse, if less than 50% of sequences were monotypic. Co-receptor usage of viral variants were predicted using a position-specific scoring matrix (PSSM) of the HIV *env* V3 loop (<https://indra.mullins.microbiol.washington.edu/webpssm/>) for Clade B viruses, the dominant strain in Peru, using the X4R5 matrix \[[@R21]\]. Sequences were submitted to GenBank (accession numbers: KU740361-KU743103) and the phylogenetic trees for entire data set are available upon request.

Biomarkers of inflammation
--------------------------

Plasma biomarkers of inflammation \[high-sensitivity C-reactive protein (hsCRP) and interleukin (IL)-6\], and of T-cell proliferation \[soluble CD25 (sCD25)\] \[[@R22]\], monocyte/macrophage activation (soluble CD163 (sCD163), soluble CD14 (sCD14) \[[@R23],[@R24]\], soluble tumor necrosis factor-two (sTNFR-2) and soluble vascular cellular adhesion molecule-1 (sVCAM-1)\] were determined by ELISA \[[@R25]\].

Quantification of nevirapine levels in plasma
---------------------------------------------

Nevirapine was protein precipitated from plasma using acetonitrile (AcN) containing an internal standard nevirapine-d4 (NVP-d4). An aliquot of the supernatant was diluted with 0.5% trifluoroacetic acid to maintain signal intensity within the linear range of the instrument. Reversed phase chromatographic separation was performed on an XBridge C18 analytical column (2.1 × 50 mm, 3.5 μm) under isocratic conditions. A binary mobile phase consisting of 0.1% formic acid in water and 0.1% formic acid in acetonitrile (72 : 28) was used and provided adequate separation. Detection and quantitation was achieved by multiple reaction monitoring (MRM); NVP and the NVP-d4 internal standard were detected using the following transitions for protonated molecular products \[M+H\]^+^: *m/z* NVP 267.0 \>107.0; *m/z* NVP-d4 271.2 \>227.9. This assay was developed to have a dynamic range of 5--5000 ng/ml NVP using a 20 μl sample of human plasma. NVP concentrations above 3000 ng/ml were considered the threshold for adequate adherence \[[@R26],[@R27]\].

Statistical analysis
--------------------

Wilcoxon two-sample test (Stata SE V12.1; StataCorp, College Station, Texas, USA) was used to compare pre-ART plasma HIV RNA, PBMC HIV DNA, and biomarkers of inflammation between participants with and without LLV during ART; within participants at time-points when LLV were and were not detected; and between participants with monotypic vs. more diverse LLV sequences during ART. A Fisher\'s exact test was used to compare: the proportion of participants receiving rifampin with vs. without LLV; the proportion of participants with vs. without CXCR4-co-receptor-utilizing (X4) variants; and the proportion of X4 variants within participants' pre-ART PBMC or plasma vs. LLV, both overall and within phylogenetic patterns. Paired *t* tests were used to compare HIV *env* divergence of LLV sequences from pre-ART PBMC and plasma (Graph Pad QuickCalcs, La Jolla, California, USA). A Wilcoxon--Mann--Whitney test compared: a) across participants with vs. without LLV biomarkers of inflammation/immune activation and log~10~ transformed NVP concentrations and b) within participants with LLV at time-points when plasma HIV RNA was vs. was not detected biomarker concentrations and log~10~ transformed NVP concentrations \[[@R28]\].

Results
=======

Clinical and immunologic factors and nevirapine levels associated with detection of low-level viremia
-----------------------------------------------------------------------------------------------------

One hundred and twenty-six ART-naive participants enrolled and were followed from 2007 to 2011 (Fig. [1](#F1){ref-type="fig"}). ART constituted of NVP or efavirenz (EFV), lamivudine (3TC) with zidovudine or stavudine (d4T) was initiated after enrollment \[[@R16]\]. HIV replication was ART-suppressed in 82 of 89 (92%) participants completing the 24-month study.

![Study schema of 126 HIV-infected antiretroviral therapy-naive adult participants with AIDS-defining illness or a CD4^+^ T-lymphocytes less than 250 cells/μl enrolled in this observational cohort study in Lima, Peru.](aids-32-1389-g001){#F1}

Analysis by participant found at least one LLV in 33 of 82 (40%) participants and no LLV in 49 of 82 (60%) (Fig. [1](#F1){ref-type="fig"}); the prevalence of LLV was greater in men (24/48, 50%) compared with women (9/34, 26%; *P* = 0.04). The detection of plasma HIV RNA BLLQ was similar in participants with vs. without LLV \[17/33 (52%) vs. 18/49 (37%), respectively\]. A total of 49 LLV episodes were detected with a median HIV RNA of 73 copies/ml (IQR: 40--139). HIV DNA was detected in two of 49 (4%) LLV specimens at 8 and 17 copies/ml in specimens with HIV RNA measurements of 94 and 310 copies/ml, respectively.

Pre-ART parameters were compared among the 82 participants who completed the study with ART suppression by whether LLV were detected. Those with vs. without LLV had similar pre-ART CD4^+^ T-cell counts and biomarkers of inflammation/immune activation (Table [1](#T1){ref-type="table"}). However, those with LLV had higher pre-ART plasma HIV RNA (*P* \< 0.001) and PBMC HIV DNA concentrations (*P* = 0.007; Table [1](#T1){ref-type="table"}). In participants with one (*n* = 17) vs. greater than one (*n* = 16) LLV, there were similar pre-ART plasma viral loads, PBMC HIV DNA loads, and biomarkers of inflammation concentrations. Within each sex, pre-ART characteristics of those with vs. without LLV were similar, regardless of the number of LLV (data not shown). The participants who were lost to follow-up (LTFU) had similar pre-ART CD4^+^ T-cell counts compared with 82 who were studied, but the former had lower pre-ART plasma HIV RNA concentrations (median log~10~ copies/ml 5.1, IQR: 4.7--5.3 vs. 5.4, IQR: 4.9--5.9, respectively; *P* = 0.008).

During ART, self-reported adherence was similar in those with vs. without LLV. NVP concentrations (matched for the study month) were similar between those with vs. without LLV when the former\'s plasma viral load was suppressed (median 6581, IQR: 5090--7800 vs. 5872, IQR: 4733--7002 ng/ml, *P* = 0.15), and at the time of their LLV (median 6516, IQR: 5439--8456 ng/ml; *P* = 0.09; Supplemental Figure 1). Among participants with LLV, NVP concentrations were similar at time-points when LLV were vs. were not detected, and similar in participants with 1 vs. more than one LLV (data not shown). NVP concentrations were evaluated in 23 participants with vs. 32 without any LLV detected during the study. In persons with LLV detected, sub-therapeutic (\<3000 ng/ml) \[[@R26],[@R27]\] NVP concentrations were found in one (33 ng/ml) of 20 specimens at the time of the LLV, and in two of 49 specimens (2859 ng/ml and 'below the limit of quantification') at time-points when their plasma HIV RNA was less than 30 copies/ml. Among participants without any LLV detected during the study, four of 47 specimens had sub-therapeutic concentrations (1258, 2564, 2618 and 2656 ng/ml,). Rifampin was reported at enrollment in six of 82 (7%) participants, including three with co-administration with NVP. These three participants had NVP levels determined, one had a sub-therapeutic plasma NVP concentration of 2564 ng/ml, but none had LLV detected at any time-point.

Sequence patterns of HIV *env* in low-level viremia
---------------------------------------------------

Single-genome HIV sequences were derived from the plasma of 28 of 33 (85%) participants with LLV, as well as their pre-ART plasma and PBMC; all with Clade B viruses. However, we were unable to amplify *env* sequences from one participant and *pol* from another of the 28.

The median number of *env* sequences generated from each specimen was: 16 (IQR: 10--26) from each of 44 of 49 LLV (5 specimens yielded no amplicons); 14 (IQR: 8--17) from four of four BLLQ, and 18 (IQR: 15--20) from pre-ART PBMC and plasma. Phylogenetic analyses of participants' LLV *env* and *pol* sequences found: all or predominantly monotypic sequences (median 81% identical sequences) in 16 of 28 (57%) participants (Fig. [2](#F2){ref-type="fig"}   a, c, d); and genetically diverse sequences in 12 of 28 (43%) participants (Fig. [2](#F2){ref-type="fig"}   b). The magnitude of the LLV were similar between participants with monotypic vs. diverse patterns of LLV.

![Representative phylogenetic trees, divergence, and plasma HIV RNA plots from four of 28 participants who had sequences generated from plasma low-level viremias (a--c) or viremias below the limit of quantification (d) (month specimens collected, in parenthesis).](aids-32-1389-g002){#F2}

![Representative phylogenetic trees, divergence, and plasma HIV RNA plots from four of 28 participants who had sequences generated from plasma low-level viremias (a--c) or viremias below the limit of quantification (d) (month specimens collected, in parenthesis).](aids-32-1389-g003){#F3}

![Representative phylogenetic trees, divergence, and plasma HIV RNA plots from four of 28 participants who had sequences generated from plasma low-level viremias (a--c) or viremias below the limit of quantification (d) (month specimens collected, in parenthesis).](aids-32-1389-g004){#F4}

![Representative phylogenetic trees, divergence, and plasma HIV RNA plots from four of 28 participants who had sequences generated from plasma low-level viremias (a--c) or viremias below the limit of quantification (d) (month specimens collected, in parenthesis).](aids-32-1389-g005){#F5}

The frequency of HIV *env* genotypes predicted to use the X4 co-receptor was higher in LLV compared with pre-ART plasma and PBMC \[LLV: 135/315 (43%) vs. pre-ART plasma: 8/160 (5%) *P* \< 0.001, and vs. pre-ART PBMC: 46/174 (26%) *P* \< 0.001\]. The detection of X4 had a similar prevalence across participants with monotypic (6/16; 38%) vs. diverse (5/12; 42%) LLV. However, the frequency of X4 variants was greater in the combined LLV sequences from participants with the monotypic vs. diverse LLV pattern \[89/183 (49%) vs. 46/132 (35%), *P* = 0.02\].

Whenever compared with pre-ART sequences, LLV *env* sequences did not diverge from the MRCA, except in two participants. One of these participants' divergent LLV clade had a monotypic pattern, whereas the other\'s had a diverse pattern. Both divergent clades were composed entirely of X4 variants, which were not detected in the pre-ART specimens of one participant (Fig. [2](#F2){ref-type="fig"}   c).

HIV *pol* sequences were derived from 27 of 33 (82%) participants' LLV. The median number of *pol* sequences generated from each of 44 of 49 LLV plasmas was: 17 (IQR: 10--25), from four of four BLLQ plasmas was 20 (IQR: 6--20), and from each of the 27 participants' pre-ART PBMC and plasmas was 16 (IQR: 13--20). The HIV *pol* sequences exhibited both the monotypic and diverse patterns, with the pattern in *pol* correlating with that in *env* in 25 of 26 (96%) participants. Novel drug-resistance mutations were detected in three of 27 (11%) participants. Two participants had a single mutant variant detected, one with V108I in one of 26 (4%) sequences (data not shown) and another with P225H in one of nine (11%) LLV sequences (Fig. [2](#F2){ref-type="fig"}   b); both of these LLV had a diverse pattern. Their NVP concentrations (*n* = 3 each, including at the time of LLV) were all in the therapeutic range. The third participant with 'emergent' resistance did not have a LLV; rather she had six monotypic sequences with V106A derived from a BLLQ during EFV-based ART; this clade regressed towards the MRCA compared with pre-ART sequences (Fig. [2](#F2){ref-type="fig"}   d). Low-level viremia *pol* sequences did not significantly diverge from the MRCA in any participant compared with their pre-ART PBMC sequences.

Inflammation and cellular activation
------------------------------------

Participants with vs. without LLV had similar pre-ART concentrations of hsCRP, IL-6, sCD25, sCD163, sTNFR2, and sVCAM-1 (Table [1](#T1){ref-type="table"}). During ART, all biomarkers decreased (*P* \< 0.001), regardless of whether LLV were or were not detected, except for hsCRP and sCD14 (Fig. [3](#F3){ref-type="fig"}). Comparisons of participants' biomarkers of inflammation during ART by the LLV *env* pattern found that those with monotypic LLV sequences had elevated sCD163 and hsCRP (*P* = 0.004) at time points with and without LLV (Fig. [3](#F3){ref-type="fig"}). In contrast, participants with diverse LLV *env* patterns had elevated sCD14 concentrations (*P* = 0.004) at times when LLV were detected (Fig. [3](#F3){ref-type="fig"}).

![Concentrations of biomarkers of inflammation and cellular determined before and during antiretroviral therapy, including comparisons between participants with monotypic low-level viremia compared with those with diverse low-level viremia.](aids-32-1389-g006){#F6}

Discussion
==========

The current study contributes novel and confirmatory findings to our understanding of the mechanisms leading to LLV. Aspects of our data confirm previous findings, including that LLV were more prevalent among participants with higher pre-ART plasma HIV RNA \[[@R29]--[@R35]\] and HIV DNA concentrations \[[@R30]\], overall LLV were not associated with poor adherence or low plasma concentrations of NVP \[[@R3],[@R34],[@R36]\], and two phylogenetic HIV *env* sequence patterns (monotypic vs. diverse sequences) were observed as previously reported \[[@R10]\], although, participants with the diverse LLV pattern in this study did not have genotypic findings supportive of virus replication as in our previous study. Novel observations include: an increased frequency of X4 variants in LLV compared with their pre-ART plasma and PBMC, with enrichment of X4 variants evident in LLV of participants with the monotypic but not those with the diverse LLV pattern; and distinct cytokine profiles between participants with the monotypic vs. diverse LLV pattern, which suggests two different mechanisms or cell types might produce LLV.

Previously, evidence suggested that LLV result from two processes. Ours \[[@R10],[@R18],[@R37]\] and others observations \[[@R3],[@R5],[@R10],[@R12],[@R38]\] found that LLV sequences were predominately monotypic \[[@R3],[@R5],[@R10],[@R12],[@R14],[@R38]\]. Monotypic HIV *env* sequences without divergence and *pol* sequences without novel drug resistance mutations \[[@R3],[@R10],[@R12],[@R37]--[@R40]\] were linked to multiple identical integration sites, which suggests that monotypic virions are produced by infected cell clones \[[@R14],[@R38]\]. Less frequently, LLV, usually with diverse sequences, clearly came from multiple full cycles of HIV replication with accumulation of multiple new drug-resistant variants and with increasing HIV sequence divergence \[[@R10]\]. However, the viral replication in the latter and other studies often did not result in virologic failure within the timeframe of the study \[[@R10],[@R12],[@R39],[@R40]\].

The current study and those of others \[[@R8],[@R41]--[@R43]\] found that LLV are more prevalent in individuals with larger vs. smaller HIV DNA loads, suggesting that a larger proviral reservoir when stimulated to transcribe DNA generates a quantity of virions that rises above the limit of detection to produce LLV \[[@R41]--[@R43]\]. Repeated detection of monotypic viruses over months or years suggests that virions are produced from an activated HIV-infected cell clone \[[@R3],[@R5],[@R10],[@R12],[@R37],[@R44]\]. In this study, participants were antiretroviral-naive, and whereas short-lived episodes of HIV replication most likely occurred on rare occasions, no participant with monotypic or the diverse LLV pattern showed convincing evidence of ongoing low-level virus replication.

Viral replication with sequence divergence would be expected to occur if antiretroviral concentrations were below the inhibitory concentration. Although in this study, a few participants with LLV had low-antiretroviral concentrations, HIV *env* divergence was observed in only two participants, one with therapeutic NVP levels and the second prescribed atazanavir-based ART. The divergent LLV clades in these two participants were constituted entirely of X4 sequences. Their *pol* sequences were monotypic, and did not diverge or encode drug-resistant variants. Thus, the combined data from these participants do not support viral replication. In this study, the virions forming the two divergent LLV clades may have been produced from archived clones without full cycles of virus replication.

Novel drug-resistance mutations were detected infrequently in LLV in this study, which agrees with other studies \[[@R2],[@R3],[@R10],[@R12],[@R39]\]. Also, the drug-resistance mutations detected in our participants (V106A, V108I, P225H) are not those typically associated with virologic failure of NNRTI-based ART regimens (i.e. K103N, Y181C, M184V, and/or G190A \[[@R45]\]) and were not in HIV *pol* clades with divergence. Both V108I and P225H were detected in LLV with therapeutic NVP concentrations. The BLLQ plasma from one participant on EFV-based ART yielded six identical sequences with V106A that confers high-level resistance, but these sequences regressed towards the MRCA, which is inconsistent with ongoing viral replication. Thus, although data from several participants include elements suggestive of HIV replication, in no instance were findings conclusive. It is possible that the three drug-resistant variants detected resulted from random mutations that occurred in the participants prior to ART, or in the two participants with only one mutant sequence that these were generated in the laboratory during reverse transcription of plasma.

Plasma antiretroviral concentrations have infrequently been assessed in conjunction with LLV \[[@R3],[@R34],[@R36],[@R46]\]. In agreement with our study, most LLV are not associated with decreased antiretroviral concentrations \[[@R3],[@R34],[@R36]\], although in one study, a sensitivity analysis found a modest association \[[@R46]\]. Co-administration of rifampin and NVP can diminish NVP concentrations because of activation of hepatic enzymes \[[@R47]\]. Our study was not well suited to evaluate this effect, as rifampin was co-administered with NVP in only three participants. Suboptimal antiretroviral concentrations at times of LLV have been reported from other studies \[[@R48]--[@R50]\], suggesting that poor-adherence or drug--drug interactions could be a cause of LLV. However, given the generally therapeutic levels in our study, this was not likely a cause of LLV. Thus, the persistent monotypic LLV and perhaps the diverse LLV observed in our study are likely distinct from those associated with sub-therapeutic antiretroviral levels, suggesting multiple processes can result in LLV.

Our observation of elevated hsCRP and sCD163 in participants with monotypic LLV *env* sequences reinforces previous studies associating inflammation with LLV \[[@R5]\]. Our finding of a different cytokine pattern, with elevated sCD14, in participants with diverse HIV *env* sequences combined with our observation that LLV were not associated with lower antiretroviral levels suggests that different inflammatory pathways may be associated with monotypic vs. diverse LLV. Alternatively, these different genotypic patterns may reflect differences in the cell populations or the genes harboring individuals' proviruses.

Given our and others' observations that inflammatory cytokines decrease after initiation of ART \[[@R25],[@R51]--[@R56]\], it seems logical that viral antigens could cause inflammation and promote cellular proliferation \[[@R5],[@R10]\], or vice-versa, in a potentially cyclic interaction. Previous studies associated sCD163 with CD4^+^ T-cell activation (by expression of CD38^+^ and HLA-DR+) \[[@R57],[@R58]\] and monocyte/macrophage activation \[[@R59]\]. We speculate that systemic inflammation (elevated hsCRP) and activated monocyte/macrophages (elevated sCD163) may drive proliferation of HIV-infected CD4^+^ T cells resulting in production of monotypic LLV \[[@R5],[@R10],[@R38],[@R40],[@R58]\]. Among our participants with diverse LLV, the elevated sCD14 concentrations, a marker of microbial translocation \[[@R60]\], could activate virion production from multiple infected clones across ~~i~~ntestinal lymphoid aggregates, consistent with others findings \[[@R61]--[@R63]\].

Our novel observation of a high frequency of X4 variants in LLV with the monotypic pattern suggests a selective advantage for the clones producing these variants. Of interest, is that not only do these clones persist, proliferate, and produce LLV during ART-suppression \[[@R44],[@R64],[@R65]\], but apparently without being targeted for destruction by the immune system.

The observation that X4 variants were enriched in LLV compared with pre-ART specimens, with a higher proportion notable in those with monotypic LLV pattern, suggests that cells harboring these variants may be more prone to produce virions. The repeated detection of monotypic X4 LLV sequences over months of ART suppression and the increased representation of X4 sequences in LLV compared with their pre-ART specimens suggest these virions emanate from long-lived cells. The expression of X4 variants in LLV of participants in this study may be related to their advanced stage of HIV disease prior to starting ART \[[@R66]\]. Although a few studies have evaluated X4 variants in LLV \[[@R44],[@R64]\], these studies did not detect X4 variants in monotypic LLV clades, possibly because participants began ART in earlier stages of HIV infection when X4 variants are less frequent \[[@R5],[@R62]\]. However, expansion of cell-associated HIV X4 variants during suppressive ART has been noted by others \[[@R64],[@R65]\]. The disproportionate detection of X4 variants in monotypic LLV in this study combined with elevated sCD163 suggests that activated naive T cells \[[@R67]\], tissue macrophages, or possibly monocytes \[[@R12],[@R68],[@R69]\], all with variable expression of CXCR4 \[[@R70],[@R71]\], could be a source of these LLV.

Our study population was limited in size; however, the number of participants and the number of LLV sequences evaluated were larger than previous reports \[[@R3],[@R10],[@R12],[@R38]\]. Plasma HIV RNA was measured quarterly in our study, which likely limited the detection of LLV, or biased detection towards individuals with more frequent LLV. This study is unique in evaluating whether HIV DNA from lysed cells may be misperceived as plasma HIV RNA. Notably HIV DNA was detected rarely in plasma from our participants and only at low levels suggesting that LLV sequences were primarily from HIV RNA.

Among individuals in our study, nearly all with therapeutic NVP concentrations, the observed associations of intermittent LLV with larger pre-ART HIV DNA reservoirs and with two patterns of inflammation (i.e. elevated hsCRP and sCD163 with monotypic and elevated sCD14 with diverse LLV genotypes) suggests multiple inflammatory pathways are linked to infected cell proliferation with production of virions. The increased X4 variants among participants with monotypic LLV compared with those with diverse LLV suggests that naive T cells may be a source of LLV \[[@R44],[@R70]\]. These findings combined with the linkage of monotypic LLV sequences with clones of infected cells actively producing viruses in other studies \[[@R14],[@R38]\] suggest that the cells producing these LLV may not be eliminated by immune surveillance either because these virions harbor escape mutations \[[@R72],[@R73]\], because of immune exhaustion \[[@R74]\] or other phenomenon \[[@R75]\], and suggest that naive T cells or macrophages may be a relevant source of LLV.
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Comparison of entry (preantiretroviral therapy) parameters between participants with versus without low-level viremias.

                                                                                        Participants without LLV[^a^](#TF1-1){ref-type="table-fn"}, medians (IQR), *n* = 49   Participants with LLV, medians (IQR), *n* = 33   *P* value[^b^](#TF1-2){ref-type="table-fn"}^,^[^c^](#TF1-3){ref-type="table-fn"}
  ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------ ----------------------------------------------------------------------------------
  Total number of visits (includes enrollment)                                          9 (9 -- 9)                                                                            9 (8 -- 9)                                       0.090
  Plasma HIV-1 RNA log~10~ (copies/ml)                                                  **5.1 (4.8 -- 5.6)**                                                                  **5.7 (5.2 -- 6.0)**                             **\<0.001**
  PBMC HIV DNA (copies/1 × 10^6^ cells)                                                 **1440 (500 -- 2200)**                                                                **2600 (1070 -- 4610)**                          **0.007**
  CD4^+^ lymphocytes (cells/μl)                                                         133 (43 -- 213)                                                                       123 (52 -- 205)                                  0.756
  High sensitivity C-reactive protein (mg/l)                                            2.9 (0.9 -- 10.9)                                                                     3.3 (1.2 -- 4.9)                                 0.647
  Interleukin-6 (pg/ml)[^c^](#TF1-3){ref-type="table-fn"}                               3.5 (2.1 -- 6.7)                                                                      2.6 (1.8 -- 4.3)                                 0.080
  Soluble CD14 (ng/ml)[^c^](#TF1-3){ref-type="table-fn"}                                3456 (3123 -- 3867)                                                                   3499 (2702 -- 4412)                              0.945
  Soluble CD25 (pg/ml)[^c^](#TF1-3){ref-type="table-fn"}                                2584 (1777 -- 3811)                                                                   2380 (1159 -- 3190)                              0.166
  Soluble CD163 (ng/ml)[^c^](#TF1-3){ref-type="table-fn"}                               2663 (1781 -- 3639)                                                                   3311 (2099 -- 4446)                              0.105
  Soluble tumor necrosis factor receptor-2 (pg/ml)[^c^](#TF1-3){ref-type="table-fn"}    4720 (4336 -- 5000)                                                                   4600 (4264 -- 5000)                              0.992
  Soluble vascular cell adhesion molecule-1 (pg/ml)[^c^](#TF1-3){ref-type="table-fn"}   1860 (1310--2539)                                                                     2045 (1274--2952)                                0.754

ART, antiretroviral therapy; LLV, low-level viremia; PBMC, peripheral blood mononuclear cell.

^a^Participants with all plasma HIV RNA less than 30 copies/ml during ART.

^b^Compared using a Wilcoxon two-sample test *P* \< 0.05 (in bold) were noted.

^c^Cytokines available from *n* = 44/49 without LLV and 33/33 with LLV.
